Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review

Steve Deitelzweig; Gregory Y H Lip

doi:10.1080/14737167.2019.1592834

Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › peer review

Originalsprog	Engelsk
Tidsskrift	Expert Review of Pharmacoeconomics & Outcomes Research
Vol/bind	19
Udgave nummer	3
Sider (fra-til)	243–244
Antal sider	2
ISSN	1473-7167
DOI	https://doi.org/10.1080/14737167.2019.1592834
Status	Udgivet - jun. 2019

Adgang til dokumentet

10.1080/14737167.2019.1592834

AUB Link

Søg efter materialet i Aalborg Universitetsbiblioteks søgemaskine

Andre filer og links

http://www.scopus.com/inward/record.url?scp=85063035616&partnerID=8YFLogxK

Citationsformater

@article{90c7d982fc534e19a7c411d8bb117822,

title = "Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review",

keywords = "Anticoagulation, direct oral anticoagulants, non-valvular atrial fibrillation, real-world evidence, stroke prevention, Rivaroxaban, Pyrazoles, Humans, Pyridones, Dabigatran, Atrial Fibrillation, Vitamin K/antagonists & inhibitors",

author = "Steve Deitelzweig and Lip, {Gregory Y H}",

year = "2019",

month = jun,

doi = "10.1080/14737167.2019.1592834",

language = "English",

volume = "19",

pages = "243–244",

journal = "Expert Review of Pharmacoeconomics & Outcomes Research",

issn = "1473-7167",

publisher = "Taylor & Francis",

number = "3",

}

Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review. / Deitelzweig, Steve; Lip, Gregory Y H.
I: Expert Review of Pharmacoeconomics & Outcomes Research, Bind 19, Nr. 3, 06.2019, s. 243–244.

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › peer review

TY - JOUR

T1 - Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation

T2 - a systematic literature review

AU - Deitelzweig, Steve

AU - Lip, Gregory Y H

PY - 2019/6

Y1 - 2019/6

KW - Anticoagulation

KW - direct oral anticoagulants

KW - non-valvular atrial fibrillation

KW - real-world evidence

KW - stroke prevention

KW - Rivaroxaban

KW - Pyrazoles

KW - Humans

KW - Pyridones

KW - Dabigatran

KW - Atrial Fibrillation

KW - Vitamin K/antagonists & inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85063035616&partnerID=8YFLogxK

U2 - 10.1080/14737167.2019.1592834

DO - 10.1080/14737167.2019.1592834

M3 - Comment/debate

C2 - 30870051

SN - 1473-7167

VL - 19

SP - 243

EP - 244

JO - Expert Review of Pharmacoeconomics & Outcomes Research

JF - Expert Review of Pharmacoeconomics & Outcomes Research

IS - 3

ER -